KALA BIO, Inc. (NASDAQ:KALA) Receives $1,158.33 Consensus Target Price from Analysts

KALA BIO, Inc. (NASDAQ:KALA) has earned a consensus rating of “Hold” from the six ratings firms that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, four have given a hold recommendation and one has assigned a buy recommendation to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $1,158.3333.

Several brokerages recently issued reports on KALA. Wall Street Zen cut KALA BIO from a “hold” rating to a “sell” rating in a research report on Sunday, July 12th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of KALA BIO in a research report on Wednesday, June 24th.

Institutional Investors Weigh In On KALA BIO

Hedge funds have recently modified their holdings of the stock. Woodline Partners LP acquired a new position in KALA BIO in the 1st quarter valued at $1,483,000. Virtu Financial LLC acquired a new stake in shares of KALA BIO in the 4th quarter worth $48,000. Jane Street Group LLC acquired a new stake in shares of KALA BIO in the 4th quarter worth $80,000. XTX Topco Ltd purchased a new stake in shares of KALA BIO in the second quarter valued at about $62,000. Finally, Geode Capital Management LLC boosted its holdings in shares of KALA BIO by 2.8% in the second quarter. Geode Capital Management LLC now owns 56,367 shares of the company’s stock valued at $268,000 after acquiring an additional 1,534 shares in the last quarter. 24.61% of the stock is owned by institutional investors and hedge funds.

KALA BIO Stock Performance

NASDAQ KALA opened at $0.78 on Thursday. The firm has a market cap of $15.14 million, a PE ratio of -0.01 and a beta of -2.26. KALA BIO has a one year low of $0.59 and a one year high of $1,030.00. The firm’s fifty day moving average is $1.82 and its two-hundred day moving average is $9.96.

KALA BIO (NASDAQ:KALA) last announced its earnings results on Friday, May 15th. The company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($8.50) by $8.36.

KALA BIO Company Profile

KALA Bio (NASDAQ: KALA) is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for ocular diseases. The company’s proprietary surface charge–based nanoparticle delivery platform is designed to enhance penetration and retention of therapeutic agents on the ocular surface. This technology is the basis for its lead product, Eysuvis (KPI-121 1.0%), an FDA-approved topical corticosteroid for short-term relief of ocular itching associated with allergic conjunctivitis.

Beyond its approved therapy, KALA Bio is advancing a pipeline of investigational drug candidates targeting inflammatory and degenerative eye conditions.